GDNF-RET signaling as a target in aromatase inhibitor resistant breast cancers

ABSTRACT: Understanding the complex molecular mechanisms underlying resistance to endocrine therapy is a major challenge in the treatment of estrogen receptor-positive (ER+) breast cancers. We have previously demonstrated that glial cell line-derived neurotrophic factor (GDNF) signaling via the receptor tyrosine kinase RET promotes estrogen independent activation of ER. Here we have addressed the relevance of GDNF-RET signaling in response to aromatase inhibitor treatment and explored the efficacy of using RET inhibitors in breast cancer models of aromatase inhibitor response and resistance. A GDNF-response gene set, identified from gene expression profiling, was demonstrated to be an independent prognostic marker of poor patient outcome and, importantly, to be predictive of poor response to aromata

ORGANISM(S): Homo sapiens

SUBMITTER: Alan Mackay 

PROVIDER: E-MEXP-3662 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress